Follow the
Money with Investorideas.com; Biotech Stocks
Point
Roberts WA, NEW YORK, NY – February 11, 2015 - Investorideas.com, a global news source
covering leading sectors including biotech, medical technology and life
sciences stocks updates its biotech stocks directory for investors following
the sector. There have been several IPO’s recently and there are an expected
100 IPO’s for the year. Recent additions include (ASND), (ENTL), (FLKS),
(ONCE), (TCON) and (ZSAN).
Read the full release
at http://www.investorideas.com/news/2015/biotech/02111.asp
Biotech February 2015
Preview
Aastrom Biosciences, Inc. (NasdaqCM:
ASTM) is the leader in developing
patient-specific expanded cellular therapies for use in the treatment of
patients with severe diseases and conditions. Aastrom markets two autologous
cell therapy products in the United States for the treatment of cartilage
repair and skin replacement. Aastrom is also developing MACI(TM), a
third-generation autologous chondrocyte implant for the treatment of cartilage
defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy
for the treatment of advanced heart failure due to ischemic dilated
cardiomyopathy.
ABBOTT LABORATORIES
(NYSE:
ABT) is a global healthcare company
devoted to improving life through the development of products and technologies
that span the breadth of healthcare. With a portfolio of leading, science-based
offerings in diagnostics, medical devices, nutritionals and branded generic
pharmaceuticals, Abbott serves people in more than 150 countries and employs
approximately 69,000 people.
Ablynx (Brussels: ABLX.BR) is a biopharmaceutical company engaged in the discovery and
development of Nanobodies®, a novel class of therapeutic proteins based on
single-domain antibody fragments, for a range of serious and life-threatening
human diseases, including inflammation, thrombosis, oncology and pulmonary
disease.
Acadia Pharmaceuticals Inc. (NasdaqGS:
ACAD) is a biopharmaceutical company focused on the development and
commercialization of innovative medicines that address unmet medical needs in
neurological and related central nervous system disorders. ACADIA has a
pipeline of product candidates led by pimavanserin, for which we have reported
positive Phase III trial results in Parkinson’s disease psychosis and which has
the potential to be the first drug approved in the United States for this
disorder. We are currently completing NDA-enabling clinical and manufacturing
activities for pimavanserin and are planning to submit an NDA with the FDA near
the end of 2014. Pimavanserin is also in Phase II development for Alzheimer’s
disease psychosis and has successfully completed a Phase II trial in
schizophrenia. ACADIA also has clinical-stage programs for chronic pain and
glaucoma in collaboration with Allergan, Inc. and two preclinical programs directed
at Parkinson’s disease and other neurological disorders. All product candidates
are small molecules that emanate from internal discoveries.
Access Pharmaceuticals, Inc. (OTC:ACCP) is an emerging
biopharmaceutical company that develops and commercializes proprietary products
for the treatment and supportive care of cancer patients. Access developed
MuGard and ProctiGard and is developing multiple follow-on products. Access
also has other advanced drug delivery technologies including CobaCyte™-mediated
targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer
delivery technology based on the natural vitamin B12 uptake mechanism.
Acorda Therapeutics, Inc. (NasdaqGS:ACOR) is a biotechnology
company focused on developing therapies that improve the lives of people with
neurological disorders. Acorda markets three FDA-approved therapies including:
AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve
walking in patients with multiple sclerosis (MS); ZANAFLEX CAPSULES®
(tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the
management of spasticity; and QUTENZA® (capsaicin) 8% Patch, for the management
of neuropathic pain associated with postherpetic neuralgia. AMPYRA is marketed
outside the United States as FAMPYRA® (prolonged-release fampridine tablets) by
Biogen Idec under a licensing agreement from Acorda. Acorda has one of the
leading pipelines in the industry of novel neurological therapies. The Company
is currently developing six clinical-stage therapies and one preclinical stage
therapy that address a range of disorders including post-stroke deficits,
epilepsy, stroke, peripheral nerve damage, spinal cord injury, neuropathic
pain, and heart failure.
Acrux Limited (ASX:ACR.AX) is
a dynamic Australian drug delivery business developing and commercialising a
range of patient-preferred pharmaceutical products for global markets, using
innovative, patented technology to administer drugs through the skin. Fast
drying, non-occlusive topical sprays or liquids provide an enhanced transdermal
delivery platform with low or no skin irritation, superior cosmetic
acceptability, and simple, accurate and flexible dosing.
Active Biotech (Stockholm:ACTI.ST;
OTC:ATVBF) a biotechnology
company, focuses on developing pharmaceuticals for the treatment of
autoimmune/inflammatory diseases and cancer in Sweden. Its projects include
Laquinimod, an orally administered compound in Phase III clinical trial
development for the treatment of autoimmune diseases, primarily multiple
sclerosis; Tasquinimod, which is in Phase III clinical trial for the treatment
of prostate cancer; and ANYARA, a protein drug in Phase II/III study for the
treatment of renal cell cancer. The company is also developing Paquinimod
(57-57), a compound primarily for the treatment of systemic sclerosis; and
RhuDex, a compound that is primarily intended to be used as a drug for the
treatment of rheumatoid arthritis. Its preclinical project product is ISI
(inhibition of S100 interactions) for producing patentable chemical compounds
that interact with S100A9, a target molecule for the quinoline compounds.
Addex Therapeutics (Swiss:ADXN.SW; OTC:ADDXF; Berlin:APE.BE) is a discovery and development stage
company focused on advancing innovative oral small molecules against rare
diseases utilizing its pioneering allosteric modulation-based drug discovery
platform. The Company's two lead products are being investigated in Phase 2
clinical testing: dipraglurant (ADX48621, an mGlu5 negative allosteric
modulator or NAM) is being developed by Addex to treat Parkinson's disease
levodopa-induced dyskinesia (PD-LID) and rare forms of dystonia; and ADX71149
(mGlu2 positive allosteric modulator or PAM) is being developed in
collaboration with Janssen Pharmaceuticals, Inc. to treat both schizophrenia
and anxiety as seen in patients suffering from major depressive disorder. Addex
is also advancing several preclinical programs including: GABA-BR positive
allosteric modulator (PAM) for Charcot-Marie-Tooth (type 1a) disease,
spasticity in patients with multiple sclerosis (MS), pain, overactive bladder
and other disorders; and mGlu4 PAM for MS, Parkinson's disease, anxiety and
other diseases. Allosteric modulators are an emerging class of small molecule
drugs which have the potential to be more specific and confer significant therapeutic
advantages over conventional ‘orthosteric’ small molecule or biological drugs.
The Company uses its proprietary discovery platform to target receptors and
other proteins that are recognized as essential for the therapeutic modulation
of important diseases with unmet medical needs. The Company is currently
focused on preserving the value of its assets, including the intellectual
property surrounding its portfolio of allosteric modulator drug candidates and
its proprietary allosteric modulator technology platform, while pursuing a
strategy to secure the resources necessary to advance the pipeline and maximize
value for shareholders. In parallel the Company continues to enter
collaborations with academic institutions, government organizations and patient
groups to advance its portfolio of drug candidates for the benefit of patients.
Adherex Technologies Inc. (OTC:ADHXF) (TSX:
AHX.TO) is a clinical-stage
biotechnology company developing Sodium Thiosulfate (STS), a chemo-protectant
against hearing loss associated with platinum-based chemotherapy. STS is being
investigated in two pediatric Phase III studies to evaluate the reduction of
ototoxicity and impact on survival.
Admedus
Ltd. (ASX:AHZ.AX) is a diversified healthcare
company focused on investing in and developing next generation technologies
with world class partners, acquiring strategic assets to grow its product and
service offerings and expanding revenues from its existing profitable medical
sales and distribution business. The Company has assets from research &
development through clinical development as well as sales, marketing and
distribution. Admedus is in the process of commercialising its innovative
tissue engineering technology for regenerative medicine. Admedus also has a
major interest in developing the next generation of vaccines with a
Brisbane-based research group led by Professor Ian Frazer. The vaccine
programmes target disease with significant global potential such as Herpes and
Human Papillomavirus.
ADOCIA (Paris:ADOC.PA;
OTC:ADOCY) a
biotechnology company, develops medicines from therapeutic proteins. The
company focuses on insulin therapy and the treatment of diabetic foot ulcer
based on its BioChaperone technological platform. Its product pipeline includes
BioChaperone PDGF-BB, which has completed Phase II clinical trials for the
treatment of diabetic foot ulcer, as well as in pre clinical stage for the
treatment of venous ulcer, and bedsores and burns; BioChaperone insulin that is
in Phase II clinical trials, as well as in pre clinical stage for the treatment
of diabetes; and BioChaperone for monoclonal antibodies, which is in pre
clinical stage.
Advanced Cell Technology Inc. (OTC:ACTC) is a Marlborough, Mass.-based biotechnology
company focused on the development and commercialization of human embryonic
stem cell (hESC) and adult stem cell technology. The company’s most advanced
products are in clinical trials for the treatment of dry age-related macular
degeneration and Stargardt’s macular degeneration. ACT’s preclinical programs
involve cell therapies for the treatment of other ocular disorders and for
diseases outside the field of ophthalmology, including autoimmune, inflammatory
and wound healing-related disorders. The company’s intellectual property
portfolio includes pluripotent stem cell platforms – hESC and induced
pluripotent stem cell (iPSC) – and other cell therapy research programs.
Advanced Medical Isotope Corporation (OTC:ADMD) is a late stage
development company engaged primarily in the development of brachytherapy
devices and medical isotopes for diagnostic and therapeutic applications.
AMIC's focus is on transitioning to full operations upon receipt of FDA
clearance for its patented brachytherapy cancer products. Brachytherapy uses
radiation to destroy cancerous tumors by placing a radioactive isotope inside
or next to the treatment area. Annual sales of brachytherapy products exceed $1
billion, about half of which are in the United States. The Company intends to
outsource material aspects of manufacturing, distribution, sales and marketing
for its products in the United States and to enter into licensing arrangements
outside of the United States, though the Company will evaluate its alternatives
before finalizing its plans.
Advaxis Inc. (NasdaqCM:ADXS) is a clinical-stage biotechnology company
developing multiple cancer immunotherapies based on its proprietary platform
intended to redirect the immune system to kill cancer. The Advaxis Lm-LLO technology, using bioengineered
live attenuated Listeria monocytogenes
bacteria, is the only known cancer immunotherapy agent shown in preclinical
studies to both generate cancer fighting T-cells directed against a cancer
antigen and neutralize Tregs and MSDCs, that protect the tumor microenvironment
from immunologic attack and contribute to tumor growth. Advaxis's lead
immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers
and is in clinical trials for three indications: Phase 2 in invasive cervical
cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The
FDA has granted Advaxis orphan drug designation for each of these three
indications. The Company plans to initiate a registrational clinical program
for cervical cancer in 2014 and has established licensing partners in India and
Asia for commercialization in those regions. Advaxis is planning to evaluate
the combination of ADXS-HPV with an anti-PD-L1 immune checkpoint inhibitor in
HPV-associated cancers. Advaxis's second immunotherapy candidate in clinical
testing will be ADXS-PSA, which is being developed to address prostate cancer.
Advaxis is planning to file an IND with the FDA and initiate a Phase 1-2
clinical study with ADXS-PSA. Advaxis is also developing ADXS-cHER2, to target
the Her2 receptor overexpressing cancers. Her2 is overexpressed in certain
solid-tumor cancers, including pediatric bone cancer (or osteosarcoma), breast
cancer, esophageal, and gastric cancer. Advaxis is developing ADXS-cHER2 for
both human and animal-health, and has seen promising results in canine
osteosarcoma, which is considered a model for human osteosarcoma. Advaxis is
pursuing a clinical program in pediatric osteosarcoma and has licensed
ADXS-cHER2 and three other immunotherapy constructs to a major animal-health
company. Advaxis is planning to file an IND for ADXS-cHER2 in Her2
overexpressing cancers.
Aeolus Pharmaceuticals, Inc (OTC:AOLS) is developing a new
class of broad-spectrum, catalytic-antioxidant compounds that protect healthy
tissue from the damaging effects of radiation. Its first compound, AEOL 10150,
is being developed, with funding from the U.S. Department of Health and Human
Services, as a medical countermeasure against chemical and radiological
weapons. Its initial target indications are as a protective agent against the
effects of acute radiation syndrome and delayed effects of acute radiation
exposure. Aeolus' strategy is to leverage the substantial investment in
toxicology, manufacturing and preclinical and clinical studies of AEOL 10150
made by U.S. government agencies, including the contract with BARDA valued,
with options, at up to $118.4 million, to efficiently develop the compound for
use in oncology.
AEterna
Zentaris Inc. (NASDAQCM:AEZS; TSX:
AEZ.TO) is a specialty biopharmaceutical
company engaged in developing and commercializing novel treatments in oncology
and endocrinology. The Company's pipeline encompasses compounds at various
stages of development.
Aethlon Medical, Inc. (OTC:
AEMD) creates innovative medical devices
to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive
Dialysis-like Affinity Platform Technology) establishes the basis for a new
class of therapeutics that target the rapid elimination of disease enabling
particles from the circulatory system of treated patients. The lead
Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a
broad-spectrum of viral pathogens as well as tumor-secreted exosomes that
suppress the immune system of cancer patients. Aethlon is also operating
under two government contracts with the Defense Advanced Research Projects
Agency (DARPA) related the development of a medical device to reduce the
incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon
subsidiary that is advancing exosome-based strategies to diagnose and monitor
cancer and infectious disease progression.
Full
directory and more: http://www.investorideas.com/membership/
Follow
the Money with Investorideas.com
Become an
Investorideas.com Member and access our online stock directories listing thousands
of publicly traded stocks in leading sectors
InvestorIdeas.com newswire is a global recognized news source. We publish
original content, third party investment commentary, contributor articles,
company news and press releases in leading sectors.
Sectors we cover in include mining, energy,
renewable energy, water stocks, food and beverage (including organic and LOHAS,
wine), defense and security, biotech, technology and mobile. We have also
recently expanded our global coverage to include Latin American stocks, sports
and entertainment.
Sign up for free news alerts at Investorideas.com
Disclaimer/ Disclosure: The Investorideas.com newswire is a
third party publisher of news and research as well as creates original content
as a news source. Original content created by investorideas is protected by
copyright laws other than syndication rights. Investorideas is a news source on
Google news syndication partners. Our site does not make recommendations for
purchases or sale of stocks or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investment involves risk and possible loss of investment. This site is
currently compensated by featured companies, news submissions, content
marketing and online advertising. Contact each company directly for press
release questions. Disclosure is posted on each release if required but
otherwise the news was not compensated for and is published for the sole
interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15
2008 - all BC investors should review all OTC and Pink sheet listed companies
for adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
Contact Investorideas.com
800 665 0411
